Evidence map›Paper›PMID 34237020›Full record

ArticleThe American journal of tropical medicine and hygiene2021

A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Taylor A Wahlig, Ben J Brintz, Melanie Prettyman, Andrew S Azman, Daniel T Leung

Open access · greenAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Taylor A Wahlig1Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah.
Ben J Brintz2Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Melanie Prettyman1Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah.
Andrew S Azman3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Daniel T Leung1Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah.
University of Utah · USJohns Hopkins University · US

Funding

University of Utah Center for Clinical and Translational Science-UL1UL1TR000105 · NCATS · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2012 to 2013
$5.1M
Multidisciplinary Pulmonary and Critical Care Training ProgramT32HL105321 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Ramsey Hachem, Robert Paine · 2010 to 2026
$4.5M
Estimating Cholera Burden with Cross-sectional Immunologic DataR01AI135115 · NIAID · UNIVERSITY OF UTAH · PI LEUNG, DANIEL TED · 2018 to 2022
$3.4M
NCATS NIH HHS UL1 TR000105NHLBI NIH HHS T32 HL105321NIAID NIH HHS R01 AI135115
6 · The paper itself

Abstract

Cholera remains a significant public health burden worldwide, and better methods for monitoring cholera incidence would enhance the effectiveness of public health interventions. The serum bactericidal assay (SBA) has been used extensively for Vibrio cholerae vaccine assessments and serosurveillance. Current SBA approaches for V. cholerae rely on colony enumeration or optical density (OD600nm) readings to measure viable bacteria following complement-mediated lysis. These methods provide titer values that are constrained to discrete dilution values and rely on bacterial outgrowth, which is time consuming and prone to variation. Detection of bacterial proteins following complement-mediated lysis presents a faster and potentially less variable alternative approach independent of bacterial outgrowth. Here, we present an SBA that measures luciferase luminescence driven by lysis-released adenylate kinase. This approach is faster and less variable than growth-dependent SBAs and directly measures continuous titer values. This novel SBA method can potentially be applied to other bacteria of interest.

Indexed as

Antibodies, BacterialCholeraCholera VaccinesCost-Benefit AnalysisEpidemiological MonitoringHumansImmunogenicity, VaccineLuminescent MeasurementsReproducibility of ResultsSeroepidemiologic StudiesSerum Bactericidal Antibody AssayTime FactorsVibrio choleraeAntibodies, BacterialCholera Vaccines

Identifiers

PMID34237020
PMCPMC8592349
OpenAlexW3177516822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.